These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9658641)

  • 21. Function of the p53 gene: choice between life and death.
    Chumakov PM
    Biochemistry (Mosc); 2000 Jan; 65(1):28-40. PubMed ID: 10702638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene p53 mutations, protein p53, and anti-p53 antibodies as biomarkers of cancer process.
    Lutz W; Nowakowska-Swirta E
    Int J Occup Med Environ Health; 2002; 15(3):209-18. PubMed ID: 12462448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression?
    Cheng L; Leibovich BC; Bergstralh EJ; Scherer BG; Pacelli A; Ramnani DM; Zincke H; Bostwick DG
    Cancer; 1999 Jun; 85(11):2455-9. PubMed ID: 10357418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis.
    Cappello F; Rappa F; David S; Anzalone R; Zummo G
    Anticancer Res; 2003; 23(2B):1325-31. PubMed ID: 12820390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer.
    van Houten VM; Tabor MP; van den Brekel MW; Kummer JA; Denkers F; Dijkstra J; Leemans R; van der Waal I; Snow GB; Brakenhoff RH
    J Pathol; 2002 Dec; 198(4):476-86. PubMed ID: 12434417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer.
    Wu YQ; Chen H; Rubin MA; Wojno KJ; Cooney KA
    Cancer Res; 2001 Dec; 61(24):8651-3. PubMed ID: 11751379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Recent advances on molecular pathology of prostate carcinoma].
    Niu HL; Tao Y
    Ai Zheng; 2003 May; 22(5):552-6. PubMed ID: 12753724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms.
    Kelly JA; Lucia MS; Lambert JR
    Cancer Lett; 2009 May; 277(1):38-47. PubMed ID: 19100681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site.
    Kauffman EC; Robinson VL; Stadler WM; Sokoloff MH; Rinker-Schaeffer CW
    J Urol; 2003 Mar; 169(3):1122-33. PubMed ID: 12576866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Critical evaluation of p53 as a prognostic marker in ovarian cancer.
    Hall J; Paul J; Brown R
    Expert Rev Mol Med; 2004 May; 6(12):1-20. PubMed ID: 15147608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde.
    Steiner MS; Zhang X; Wang Y; Lu Y
    Cancer Res; 2000 Aug; 60(16):4419-25. PubMed ID: 10969787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [TP53 tumor suppressor gene: 20 years (and ten thousand mutations) later].
    Hainaut P
    Bull Cancer; 2000 Jan; 87(1):11-8. PubMed ID: 10673626
    [No Abstract]   [Full Text] [Related]  

  • 33. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.
    Tepper CG; Gregg JP; Shi XB; Vinall RL; Baron CA; Ryan PE; Desprez PY; Kung HJ; deVere White RW
    Prostate; 2005 Dec; 65(4):375-89. PubMed ID: 16037992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
    Lee SE; Jin RJ; Lee SG; Yoon SJ; Park MS; Heo DS; Choi H
    Anticancer Res; 2000; 20(1A):417-22. PubMed ID: 10769689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 mutation heterogeneity in cancer.
    Soussi T; Lozano G
    Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
    Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic characteristics of prostate cancer.
    Huncharek M; Muscat J
    Cancer Epidemiol Biomarkers Prev; 1995 Sep; 4(6):681-7. PubMed ID: 8547836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 gene mutational rate, Gleason score, and BK virus infection in prostate adenocarcinoma: Is there a correlation?
    Russo G; Anzivino E; Fioriti D; Mischitelli M; Bellizzi A; Giordano A; Autran-Gomez A; Di Monaco F; Di Silverio F; Sale P; Di Prospero L; Pietropaolo V
    J Med Virol; 2008 Dec; 80(12):2100-7. PubMed ID: 19040285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 apoptotic response to DNA damage dependent on bcl2 but not bax in head and neck squamous cell carcinoma lines.
    Crowe DL; Sinha UK
    Head Neck; 2006 Jan; 28(1):15-23. PubMed ID: 16302195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic alterations in human prostate cancer: a review of current literature.
    Ozen M; Pathak S
    Anticancer Res; 2000; 20(3B):1905-12. PubMed ID: 10928125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.